Key result
Serum levels of MMP-9, GDF-8, and FSTN successfully discriminated Duchenne Muscular Dystrophy patients from healthy controls and were useful for carrier detection (p < 0.05).
Why the study?
Do serum levels of MMP-9, GDF-8, and FSTN accurately distinguish DMD patients from healthy controls and detect carriers?
Observational
Do serum levels of MMP-9, GDF-8, and FSTN accurately distinguish DMD patients from healthy controls and detect carriers?
p-value: p=< 0.05
Serum biomarkers MMP-9, GDF-8, and FSTN show potential for diagnosing Duchenne Muscular Dystrophy, detecting carriers, and monitoring disease progression, potentially outperforming traditional CK levels.
No takes yet. Share an insight, caveat, or question.
May support DMD biomarker use for diagnosis and carriers; leaves open prospective validation before clinical adoption.
Anaya-Segura et al. (2015) conducted an observational in Duchenne Muscular Dystrophy. Serum levels of MMP-9, GDF-8, and FSTN vs. Healthy controls was evaluated on Discrimination between DMD and controls, and carrier detection (p=< 0.05). Serum levels of MMP-9, GDF-8, and FSTN successfully discriminated Duchenne Muscular Dystrophy patients from healthy controls and were useful for carrier detection (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: